Clinical trial NCT00932217 - References

G-CSF, Multiple Myeloma, Febrile Episode, Filgrastim, Leograstim — Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma

Citation(s)

•   Azzarà A, Carulli G, Rizzuti-Gullaci A, Capochiani E, Petrini M
  Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis. Am J Hematol. 2001 Apr;66(4):306-7.
•   Bodey GP, Buckley M, Sathe YS, Freireich EJ
  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 Feb;64(2):328-40.
•   Carter CR, Whitmore KM, Thorpe R
  The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol. 2004 Mar;75(3):515-22. Epub 2003 Dec 4.
•   Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B
  Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005 Jun 20;23(18):4198-214.
•   de Arriba F, Lozano ML, Ortuño F, Heras I, Moraleda JM, Vicente V
  Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells. Br J Haematol. 1997 Feb;96(2):418-20.
•   Fischer JC, Frick M, Wassmuth R, Platz A, Punzel M, Wernet P
  Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol. 2005 Sep;130(5):740-6.
•   Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group
  A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003 Jan;14(1):29-35.
•   Höglund M, Smedmyr B, Bengtsson M, Tötterman TH, Cour-Chabernaud V, Yver A, Simonsson B
  Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers--a comparative study. Eur J Haematol. 1997 Sep;59(3):177-83.
•   Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ
  Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006 Sep;134(5):517-25.
•   Layton JE, Hall NE
  The interaction of G-CSF with its receptor. Front Biosci. 2006 Sep 1;11:3181-9. Review.
•   Martin-Christin F
  Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs. 2001 Mar;12(3):185-91. Review.
•   Mattii L, Azzarà A, Fazzi R, Carulli G, Chimenti M, Cecconi N, Galimberti S, Petrini M
  Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA. Leuk Res. 2005 Nov;29(11):1285-92.
•   Molineux G
  The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10(11):1235-44. Review.
•   Oh-eda M, Hasegawa M, Hattori K, Kuboniwa H, Kojima T, Orita T, Tomonou K, Yamazaki T, Ochi N
  O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem. 1990 Jul 15;265(20):11432-5.
•   Ono M
  Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). Eur J Cancer. 1994;30A Suppl 3:S7-11. Review.
•   Ribeiro D, Veldwijk MR, Benner A, Laufs S, Wenz F, Ho AD, Fruehauf S
  Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion. 2007 Jun;47(6):969-80.
•   Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, et al
  Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A(3):319-24.
•   Watts MJ, Addison I, Long SG, Hartley S, Warrington S, Boyce M, Linch DC
  Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol. 1997 Aug;98(2):474-9.

Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma

Details for clinical trial NCT00932217